Prognostic potential of the telomerase subunit human telomerase reverse transcriptase in tumor tissue and nontumorous mucosa from patients with colorectal carcinoma

Cancer

Volumn 95, Issue 10, 2002, Pages 2103-2111

  Gertler, Ralf ^a   Rosenberg, Robert ^a   Stricker, Dominik ^a   Werner, Martin ^a   Lassmann, Silke ^a   Ulm, Kurt ^a   Nekarda, Hjalmar ^a   Siewert, Joerg Ruediger ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Carcinogenesis; Colorectal carcinoma; Human telomerase reverse transcriptase; Prognosis; Real time polymerase chain reaction; Telomerase

Indexed keywords

MESSENGER RNA; MOLECULAR MARKER; RNA DIRECTED DNA POLYMERASE; TELOMERASE;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; CATALYSIS; CELL IMMORTALIZATION; COLORECTAL CARCINOMA; CORRELATION ANALYSIS; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME STABILITY; ENZYME SUBUNIT; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPHATIC SYSTEM; MAJOR CLINICAL STUDY; MALE; MOLECULAR BIOLOGY; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERE;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TELOMERASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0037110676     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10939     Document Type: Article

References (46)

1. Blackburn EH. Structure and function of telomeres. Nature. 1991;350:569-573.
2. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990;346:866-868.
3. Hoos A, Nekarda H. Telomerase - Potential und grenzen der klinischen anwendbarkeit. Dtsch Med Wschr. 1999;124:223-230.
4. Morin GB. The human telomere transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell. 1989;59:521-529.
5. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011-2015.
6. Chadeneau C, Hay K, Hirte HW, Gallinger S, Bacchetti S. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res. 1995;55: 2533-2536.
7. Engelhardt M, Drullinsky P, Guillem J, Moore MAS. Telomerase and telomere length in the development and progression of premalignant lesions to colorectal cancer. Clin Cancer Res. 1997;3:1931-1941.
8. Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res. 2000;6:2696-2701.
9. Feng J, Funk WD, Wang SS, et al. The RNA component of human telomerase. Science. 1995;269:1236-1241.
10. Nakamura TM, Morin GB, Chapman KB, et al. Telomerase catalytic subunit homologs from fission yeast and human. Science. 1997;277:955-959.
11. Hisatomi H, Nagao K, Kanamaru T, Endo H, Tomimatsu M, Hikiji K. Levels of telomerase catalytic subunit mRNA as a predictor of potential malignancy. Int J Oncol. 1999;14:727-732.
12. Liu BCS, LaRose I, Weinstein LJ, Ahn M, Weinstein MH, Richie JP. Expression of telomerase subunits in normal and neoplastic prostate epithelial cells isolated by laser capture microdissection. Cancer. 2001;92:1943-1948.
13. Yan P, Saraga EP, Bouzourene H, Bosman FT, Benhattar J. Expression of telomerase genes with telomerase activity in human colorectal carcinogenesis. J Pathol. 2001;193:21-26.
14. Meyerson M, Counter CM, Eaton EN, et al. HEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell. 1997;90:785-795.
15. Nakayama Y, Tahara H, Tahara E, et al. Telomerase activation by hTERT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet. 1998;18:65-68.
16. Weinrich SL, Pruzan R, Ma L, et al. Reconstitution of human telomerase with template RNA component hTERC and the catalytic protein subunit hTERT. Nat Genet. 1997;18:65-68.
17. Bodnar AG, Ouelette M, Frolkins M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349-352.
18. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999;10:1164-1170.
19. Lustig AJ. Crisis intervention: The role of telomerase. Proc Natl Acad Sci USA. 1999;96:3339-3341.
20. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MV, Weinberg RA. Creation of human tumor cells with defined genetic elements. Nature. 1999;400:464-468.
21. Sobin LH, Wittekind C. TNM Classification of Malignant Tumors, 5th Ed. New York: Wiley-Liss, Inc., 1997.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Cox DR. Regression models and life-tables. J R Stat Soc. 1972;34:187-220.
24. Breimann L, Friedmann JH, Ohlsen RA, Stone CJ. Classification and Regression Trees (CART). Belmont, CA: Wadsworth International Group, 1984.
25. Nakamura Y, Tahara E, Tahara H, Yasui W, Tahara E, Ide T. Quantitative reevaluation of telomerase activity in cancerous and noncancerous gastrointestinal tissues. Mol Carcinog. 1999;26:312-320.
26. Niyama H, Mizumoto K, Sato N, et al. Quantitative analysis of hTERT mRNA expression in colorectal cancer. Am J Gastroenterol. 2001;96:1895-1900.
27. Tahara H, Yasui W, Tahara E, et al. Immuno-histochemical detection of human telomerase catalytic component, hTERT, in human colorectal tumor and non-tumor tissue sections. Oncogene. 1999;18:1561-1567.
28. Poremba C, Scheel C, Hero B, et al. Telomerase activity and telomerase subunits gene expression patterns in neuroblastoma: A molecular and immunohistochemical study establishing prognostic tools for fresh-frozen and paraffin-embedded tissues. J Clin Oncol. 2000;18:2582-2592.
29. Bieche I, Nogues C, Paradis V, et al. Quantitation of hTERT gene expression in sporadic breast tumors with real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res. 2000;6:452-459.
30. Komiya T, Kawase I, Nitta T, et al. Prognostic significance of hTERT expression in non-small cell lung cancer. Int J Oncol. 2000;16:1173-1177.
31. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer. 2000;88:1739-1757.
32. De Kok JB, Ruers TJM, van Muijen GNP, van Bokhoven A, Willems HL, Swinkels DW. Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues. Clin Chem. 2000;46:313-318.
33. Kolquist KA, Ellisen LW, Counter CM, et al. Expression of TERT in early premalignant lesions and a subset of cells in normal tissues. Nat Genet. 1998;19:182-186.
34. Rohde V, Sattler HP, Bund T, et al. Expression of the human telomerase reverse transcriptase is not related to telomerase activity in normal and malignant renal tissue. Clin Cancer Res. 2000;6:4803-4809.
35. Kanaya T, Kyo S, Takahura M, Ito H, Namiki M, Inoue M. hTERT is a critical determinant of telomerase activity in renal-cell carcinoma. Int J Cancer. 1998;78:539-543.
36. Ulaner GA, Hu J-F, Vu TH, Oruganti H, Giudice LC, Hoffman AR. Regulation of telomerase reverse transcriptase (hTERT) in normal and neoplastic ovary, endometrium and myometrium. Int J Cancer. 2000;85:330-335.
37. Ulaner GA, Hu JF, Vu TH, Giudice LC, Hoffman AR. Tissuespecific alternate splicing of human telomerase reverse transcriptase (hTERT) influences telomere lengths during human development. Int J Cancer. 2001;91:644-649.
38. Colgin LM, Wilkinson C, Englezou A, Kilian A, Robinson MO, Reddel RR. The hTERT alpha splice variant is a dominant negative inhibitor of telomerase activity. Neoplasia. 2000;2: 426-432.
39. Yi X, White DM, Aisner DL, Baur JA, Wright WE, Shay JW. An alternate splicing variant of the human telomerase catalytic subunit inhibits telomerase activity. Neoplasia. 2000;2:433-440.
40. Nakamura KI, Furugori E, Esaki Y, et al. Correlation of telomere lengths in normal and cancer tissue in the large bowel. Cancer Lett. 2000;158:179-184.
41. De Kok JB, Schalken JA, Aalders TW, Ruers TJM, Willems HL, Swinkels DW. Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas. Int J Cancer. 2000;87:217-220.
42. Kumaki F, Kawai T, Hiroi S, et al. Telomerase activity and expression of human telomerase RNA component and human telomerase reverse transcriptase in lung carcinomas. Hum Pathol. 2001;32:188-195.
43. Wisman GBA, Knol AJ, Helder MN, et al. Telomeres in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer. 2001;91:658-664.
44. Greaves M. Is telomerase activity in cancer due to selection of stem cells and differentiation arrest? Trends Genet. 1996; 12:127-128.
45. Liotta LA, Kohn EC. The microenvironment of the tumourhost interface. Nature. 2001;411:375-379.
46. Hodes R. Molecular targeting of cancer: Telomeres as targets. Proc Natl Acad Sci USA. 2001;98:7649-7651.